Drug-induced Fatty Liver Disease: Pathogenesis and Treatment (CROSBI ID 301924)
Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija
Podaci o odgovornosti
Omanovic Kolaric, Tea ; Nincevic, Vjera ; Kuna, Lucija ; Duspara, Kristina ; Bojanic, Kristina ; Vukadin, Sonja ; Raguz-Lucic, Nikola ; Wu, George Y ; Smolic, Martina
engleski
Drug-induced Fatty Liver Disease: Pathogenesis and Treatment
Metabolic dysfunction-associated fatty liver disease (commonly known as MAFLD) impacts global health in epidemic proportions, and the resulting morbidity, mortality and economic burden is enormous. While much attention has been given to metabolic syndrome and obesity as offending factors, a growing incidence of polypharmacy, especially in the elderly, has greatly increased the risk of drug-induced liver injury (DILI) in general, and drug-induced fatty liver disease (DIFLD) in particular. This review focuses on the contribution of DIFLD to DILI in terms of epidemiology, pathophysiology, the most common drugs associated with DIFLD, and treatment strategies.
Metabolic dysfunction-associated fatty liver disease, Drug-induced liver injury, Reactive oxygen species, Free fatty acids, Pharmacogenetics
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
9 (5)
2021.
731-737
objavljeno
2225-0719
2310-8819
10.14218/JCTH.2020.00091
Povezanost rada
nije evidentirano